Aliyamma Samuel
Adult Health · Jamaica, NYNPI 1023114352
Payments from drug & device makers
Across 342 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$965
- Abbott$881
- Corcept Therapeutics$822
- Lilly USA, LLC$762
- AstraZeneca$605
- plus $5K from 33 others
What the payments were for
- Food & beverage$10,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$587
- FREESTYLE LIBRE 3$421
- DEXCOM G6 TRANSMITTER$369
- Pogo Automatic Blood Glucose Monitoring System$222
- REZDIFFRA$133
- Strensiq$132
- FreeStyle Libre 2$125
- FARXIGA$125
- EVENITY$125
- Yorvipath$125
- VOQUEZNA$125
- Veltassa$125
- AFREZZA$124
- TEPEZZA$124
- Korlym$122
- t-slim insulin pump$117
- MYCAPSSA$112
- RECORLEV$107
How this compares
$10,355 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $92,128 |
| JardianceEmpagliflozin | 62 | $84,579 |
| TrulicityDulaglutide | 40 | $58,364 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $51,418 |
| FarxigaDapagliflozin Propanediol | 48 | $47,986 |
| JanuviaSitagliptin Phosphate | 38 | $46,919 |
| ProliaDenosumab | 19 | $30,358 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $23,611 |
| Novolog FlexpenInsulin Aspart | 110 | $19,481 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $14,268 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 12 | $6,648 |
| NovologInsulin Aspart | 26 | $5,401 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,276 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 65 | $3,957 |
| Levemir FlexpenInsulin Detemir | 26 | $3,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,476 | $97,52997 claims |
| MerckJanuvia, Janumet | $43 | $61,18653 claims |
| Lilly USA, LLCTrulicity | $762 | $58,36440 claims |
| AstraZenecaFarxiga | $605 | $47,98648 claims |
| AmgenProlia | $965 | $30,35819 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $494 | $1,417118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Jamaica
- Nermala PersaudJamaica$28K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.